Current treatment strategy of acute promyelocytic leukemia

作     者：Jianqing Mi 

作者机构：Department of HematologyShanghai Institute of HematologyRui-Jin HospitalShanghai JiaoTong University School of MedicineShanghai 200025China 

出 版 物：《Frontiers of Medicine》 (医学前沿（英文版）)

年 卷 期：2011年第5卷第4期

页      面：341-347页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：acute promyelocytic leukemia all-trans retinoic acid arsenic trioxide 

摘      要：Acute promyelocytic leukemia(APL)is a unique subtype of acute myeloid leukemia(AML).The prognosis of APL has changed from the worst among the AMLs to currently the *** application of all-trans retinoic acid(ATRA)in the induction therapy of APL decreases the high mortality of newly diagnosed patients,thereby significantly improving the response *** combined with anthracycline-based chemotherapy is the current standard treatment,and for high-risk patients,high doses cytarabine have a beneficial effect on relapse *** recent years,the indications of arsenic trioxide(ATO)therapy for APL have been extended from the salvage therapy for relapse patients to the first-line treatment of de novo *** introduction of both ATRA and ATO represents great achievements in translational *** this review article,we discuss the therapeutic strategies for this disease,including the initial approaches to newly diagnosed patients,prevention,and treatment of side effects and relapse to ensure the best and timely treatment for each newly diagnosed APL patient.